BiotechTube

Zidovudine + Didanosine

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AIDS Dementia Complex

Conditions

AIDS Dementia Complex, HIV Infections

Trial Timeline

— → Sep 1, 1992

NCT ID
NCT00000657

About Zidovudine + Didanosine

Zidovudine + Didanosine is a phase 2 stage product being developed by Bristol Myers Squibb for AIDS Dementia Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT00000657. Target conditions include AIDS Dementia Complex, HIV Infections.

What happened to similar drugs?

4 of 11 similar drugs in AIDS Dementia Complex were approved

Approved (4) Terminated (1) Active (7)
✅TruvadaGilead SciencesApproved
✅bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved
✅Emtricitabine and TenofovirGilead SciencesApproved
✅Maraviroc + Vardenafil + Maraviroc + PlaceboPfizerApproved
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00001025Phase 2Completed
NCT00000671Phase 2Completed
NCT00000979Phase 2Completed
NCT00001024Pre-clinicalCompleted
NCT00000637Phase 3Completed
NCT00000657Phase 2Completed
NCT00000656Phase 1Completed
NCT00002035Pre-clinicalCompleted
NCT00000823Phase 2Completed

Competing Products

20 competing products in AIDS Dementia Complex

See all competitors
ProductCompanyStageHype Score
EsomeprazoleAstraZenecaPhase 3
40
EsomeprazoleAstraZenecaPhase 3
40
SelumetinibAstraZenecaPhase 1/2
24
MetforminMerckPhase 2/3
34
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placeboMerckPhase 2
27
Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3
40
rituximab + CHOPRochePhase 2
27
R-EPOCH and cARTRochePhase 2
35
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TCGilead SciencesPre-clinical
18
Switch to E/C/FTC/TAF dailyGilead SciencesPhase 1/2
32
Biktarvy + SymtuzaGilead SciencesPhase 3
40
TruvadaGilead SciencesApproved
43
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOSGilead SciencesPhase 2/3
42
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved
35
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral TabletGilead SciencesPhase 2
35
E/C/F/TAF + E/C/F/TAF (Low Dose)Gilead SciencesPhase 2/3
38
EVG + Background regimenGilead SciencesPhase 2/3
30
Emtricitabine and TenofovirGilead SciencesApproved
39
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tabletsGilead SciencesPhase 3
47
MaravirocPfizerPhase 1
29